Literature DB >> 1630849

Increased serum osteocalcin levels in patients with paraplegia.

P Pietschmann1, P Pils, W Woloszczuk, R Maerk, D Lessan, J Stipicic.   

Abstract

Osteocalcin(OC) is a specific serum parameter of bone formation. Since bone metabolism disturbances, including osteoporosis, are seen in paraplegia, the serum levels of OC, midregional parathyroid hormone(mPTH), intact para-thyroid hormone (iPTH) and calcitonin (CT) serum levels were determined in 13 patients with paraplegia or tetraplegia and 15 control subjects by radioimmunoassay in a cross sectional study. In addition, the urinary hydroxyproline/creatine and the urinary calcium/creatinine ratio was determined. Serum OC levels were significantly increased in the patients with spinal cord injury (p less than 0.02), whereas serum levels of mPTH, iPTH and CT were not statistically different. The urinary hydroxyproline/creatinine ratio was significantly higher in the patients than in the controls (p less than 0.02), and the urinary calcium/creatinine ratio also tended to be higher in the patients. In a follow up study over 6 months after spinal cord injury, serum OC, serum iPTH, urinary hydroxyproline/creatinine ratio and the calcium/creatinine ratio were determined in 6 patients at monthly intervals. Hyperhydroxyprolinuria preceded the gradual increase of serum OC from normal to clearly elevated levels. Our data suggest that increased bone resorption in paraplegia is linked to an enhanced osteoblastic activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1630849     DOI: 10.1038/sc.1992.56

Source DB:  PubMed          Journal:  Paraplegia        ISSN: 0031-1758


  14 in total

1.  Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.

Authors:  Jeffrey I Mechanick; Kan Liu; David M Nierman; Adam Stein
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

Review 2.  Bone loss and muscle atrophy in spinal cord injury: epidemiology, fracture prediction, and rehabilitation strategies.

Authors:  Lora Giangregorio; Neil McCartney
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

3.  Bone loss and impaired fracture healing in spinal cord injured mice.

Authors:  W-G Ding; S-D Jiang; Y-H Zhang; L-S Jiang; L-Y Dai
Journal:  Osteoporos Int       Date:  2010-05-06       Impact factor: 4.507

4.  Evaluation of bone mineral density in patients with spinal cord injury.

Authors:  Kurtulus Kaya; Canan Aybay; Sumru Ozel; Nilufer Kutay; Ordu Gokkaya
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

5.  Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.

Authors:  J S Bubbear; A Gall; F R I Middleton; M Ferguson-Pell; R Swaminathan; R W Keen
Journal:  Osteoporos Int       Date:  2010-04-01       Impact factor: 4.507

Review 6.  Osteoporosis after spinal cord injury.

Authors:  Sheng-Dan Jiang; Li-Yang Dai; Lei-Sheng Jiang
Journal:  Osteoporos Int       Date:  2005-10-11       Impact factor: 4.507

7.  The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study.

Authors:  Christina V Oleson; Ralph J Marino; Christopher S Formal; Christopher M Modlesky; Benjamin E Leiby
Journal:  Spinal Cord       Date:  2020-02-13       Impact factor: 2.772

8.  International spinal cord injury endocrine and metabolic extended data set.

Authors:  W A Bauman; J M Wecht; F Biering-Sørensen
Journal:  Spinal Cord       Date:  2017-03-21       Impact factor: 2.772

Review 9.  Skeletal adaptations to alterations in weight-bearing activity: a comparison of models of disuse osteoporosis.

Authors:  Lora Giangregorio; Cameron J R Blimkie
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

10.  Five-year longitudinal bone evaluations in individuals with chronic complete spinal cord injury.

Authors:  Douglas E Garland; Rodney H Adkins; Charles A Stewart
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.